GSEU - ETF AI Analysis

Top Page

Goldman Sachs ActiveBeta Europe Equity ETF (GSEU)

Rating:63Neutral

Price Target:―

GSEU, the Goldman Sachs ActiveBeta Europe Equity ETF, has a solid overall rating that reflects a core of high-quality European leaders, especially in healthcare and financials. Strong holdings like Novartis, AstraZeneca, and HSBC support the fund with robust financial performance, positive earnings outlooks, and generally reasonable valuations. Some positions, such as SAP with weaker technical trends and signs of potential overvaluation, along with mixed technical and valuation signals in other holdings, highlight the main risk: exposure to stocks that may be expensive or facing short-term market pressure despite strong fundamentals.

Positive Factors

Solid Recent Performance

The ETF has shown steady gains over the past three months and year-to-date, indicating positive recent momentum.

Strong Leading Holdings

Several of the largest positions, such as ASML, Roche, Novartis, HSBC, Siemens, and Santander, have delivered strong or steady performance, helping support the fund’s returns.

Broad European Diversification

Holdings spread across major European markets and multiple sectors, including financials, industrials, health care, and consumer stocks, help reduce reliance on any single country or industry.

Negative Factors

Sector Concentration in Financials and Industrials

A large share of the portfolio is in financial and industrial companies, which can make the fund more sensitive to downturns in these areas.

Several Weak Top Holdings

Some key positions like AstraZeneca, SAP, Nestlé, and Shell have shown weaker recent performance, which can drag on overall returns if the trend continues.

Moderate Fund Size

With a relatively modest asset base, the ETF may be less liquid than larger funds, which could matter for investors trading bigger amounts.

GSEU vs. SPDR S&P 500 ETF (SPY)

AUM121.28M

RegionEurope

Expense Ratio0.25%

Beta0.63

IssuerGoldman Sachs

Inception DateMar 02, 2016

Dividend Yield2.62%

Asset ClassEquity

Index TrackedGoldman Sachs ActiveBeta Europe Equity

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume12,619

30 Day Avg. Volume13,983

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

51.76

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering352

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

GSEU Summary

The Goldman Sachs ActiveBeta Europe Equity ETF (GSEU) is a fund that follows the Goldman Sachs ActiveBeta Europe Equity index, aiming to capture stock market opportunities across many European countries. It holds a wide mix of companies of different sizes and sectors, including well-known names like Nestlé, ASML, HSBC, and AstraZeneca. Someone might invest in this ETF to get broad, diversified exposure to European stocks in a single investment, with the potential for long-term growth. A key risk is that its value can rise or fall with the European stock market and economic conditions in that region.

How much will it cost me?The Goldman Sachs ActiveBeta Europe Equity ETF (Ticker: GSEU) has an expense ratio of 0.25%, meaning you’ll pay $2.50 per year for every $1,000 invested. This cost is lower than average for actively managed funds because it uses a systematic strategy to balance multiple factors, making it more efficient than many traditional active funds.

What would affect this ETF?The GSEU ETF, which focuses on European equities, could benefit from economic recovery in Europe, increased demand for healthcare and technology innovations, and stable financial sector performance, given its significant exposure to these areas. However, it may face challenges from rising interest rates, regulatory changes in Europe, or economic slowdowns that could negatively impact industrial and consumer sectors. Its diversified holdings across developed European markets provide some resilience against sector-specific risks.

GSEU Top 10 Holdings

GSEU leans heavily into Europe’s financial and healthcare powerhouses, with ASML acting as the fund’s main engine, rising on strong demand for chipmaking equipment. Roche, Novartis, and HSBC are also pulling their weight, providing steady to rising support from defensive pharma and global banking. On the flip side, SAP has been lagging, and consumer staple giant Nestlé is losing a bit of steam, slightly dulling returns. Overall, the ETF is broadly spread across developed Europe, but big banks, drugmakers, and ASML set the tone.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	3.49%	$4.25M	€464.34B	67.81%	76 Outperform
ROG	Roche Holding AG	2.13%	$2.59M	CHF279.83B	41.58%	73 Outperform
NOVN	Novartis AG	1.92%	$2.33M	CHF218.15B	19.92%	80 Outperform
HSBA	HSBC Holdings	1.77%	$2.15M	£220.77B	51.99%	80 Outperform
AZN	AstraZeneca	1.71%	$2.08M	£210.86B	19.89%	80 Outperform
SAN	Banco Santander	1.43%	$1.74M	€158.18B	124.88%	73 Outperform
NESN	Nestlé SA	1.28%	$1.55M	CHF185.72B	12.00%	71 Outperform
SAP	SAP SE	1.27%	$1.54M	€194.20B	-37.58%	66 Neutral
SIE	Siemens	1.24%	$1.51M	€199.98B	24.44%	74 Outperform
SHEL	Shell (UK)	1.23%	$1.50M	£158.23B	4.31%	73 Outperform

GSEU Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

45.37

Positive

100DMA

44.34

Positive

200DMA

42.77

Positive

Market Momentum

MACD

0.65

Negative

RSI

61.65

Neutral

STOCH

72.70

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSEU, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 46.85, equal to the 50-day MA of 45.37, and equal to the 200-day MA of 42.77, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 61.65 is Neutral, neither overbought nor oversold. The STOCH value of 72.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSEU.

GSEU Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
GSEU	―	―	$121.28M	0.25%	―
VGK	―	―	$31.27B	0.06%	―
SPEU	―	―	$767.55M	0.07%	―
DBEU	―	―	$679.36M	0.45%	―
FEUZ	―	―	$123.71M	0.80%	―
FLEE	―	―	$122.38M	0.09%	―

Performance Comparison

GSEU

Goldman Sachs ActiveBeta Europe Equity ETF

47.56

12.35

35.08%

VGK

Vanguard FTSE Europe ETF

―

SPEU

SPDR Portfolio Europe ETF

―

DBEU

Xtrackers MSCI Europe Hedged Equity ETF

―

FEUZ

First Trust Eurozone AlphaDEX ETF

―

FLEE

Franklin FTSE Europe ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents